Skip to main content
Clinical Trials/NCT05430204
NCT05430204
Completed
Not Applicable

Continuous Glucose Monitoring for Screening for Diabetes in Pregnancy:A Comparative Effectiveness Randomized Control Trial (PRECISE)

The University of Texas Health Science Center, Houston1 site in 1 country1,628 target enrollmentMarch 7, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gestational Diabetes
Sponsor
The University of Texas Health Science Center, Houston
Enrollment
1628
Locations
1
Primary Endpoint
Number of Neonates That Show Composite Adverse Neonatal Outcome
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The purpose of this study is to evaluate whether Continuous glucose monitoring (CGM) for diagnosis of gestational diabetes mellitus (GDM) improves maternal and neonatal outcomes related to GDM and to evaluate whether CGM for GDM diagnosis reduces the health system costs for mother-infant dyads compared to usual care

Registry
clinicaltrials.gov
Start Date
March 7, 2023
End Date
September 16, 2024
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Michal Fishel Bartal

Assistant Professor

The University of Texas Health Science Center, Houston

Eligibility Criteria

Inclusion Criteria

  • 24-30 weeks gestation undergoing GDM screening

Exclusion Criteria

  • Known diagnosis of Type I and II DM
  • History of bariatric surgery
  • Major fetal anomalies
  • Unwilling to use CGM for GDM screening
  • Incarcerated subjects
  • History of allergic reaction to any of CGM metals or adhesives in contact with the skin

Outcomes

Primary Outcomes

Number of Neonates That Show Composite Adverse Neonatal Outcome

Time Frame: From birth to about 28 days of life.

Composite adverse neonatal outcome include one or more of the following: * Large for Gestational Age(LGA) is described as weight over 90th percentile of the expected value according to gestational age (using the nomogram by Duryea EL et al) * Shoulder Dystocia is defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head to deliver the fetal body after the fetal head has been delivered * Birth injury: skull, clavicular, humerus fracture, or brachial plexus injury * Neonatal hypoglycemia: less than 40 mg/dL in the first 24 hours of life and less than 50 mg/dL after or requiring medical therapy * Respiratory distress is described as the need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure, or ventilation at the first 24 hours of life * Fetal or neonatal death (within 28 days of birth)

Number of Neonates That Show Adverse Neonatal Outcome of Large for Gestational Age(LGA)

Time Frame: at time of birth

LGA is described as weight over 90th percentile of the expected value according to gestational age (using the nomogram by Duryea EL et al)

Number of Neonates That Show Adverse Neonatal Outcome of Shoulder Dystocia

Time Frame: at time of birth

Shoulder dystocia is defined as the need for any extra maneuvers, other than gentle downward traction of the fetal head to deliver the fetal body after the fetal head has been delivered

Number of Neonates That Show Adverse Neonatal Outcome of Birth Injury

Time Frame: at time of birth

Birth injury: skull, clavicular, humerus fracture, or brachial plexus injury

Number of Neonates That Show Adverse Neonatal Outcome of Neonatal Hypoglycemia

Time Frame: from birth to discharge (about 3-15 days)

Neonatal hypoglycemia: less than 40 mg/dL in the first 24 hours of life and less than 50 mg/dL after or requiring medical therapy

Number of Fetal or Neonatal Deaths

Time Frame: within 28 days of birth

Number of Neonates That Show Adverse Neonatal Outcome of Respiratory Distress

Time Frame: from birth to discharge (about 3-15 days)

Respiratory distress is described as the need for at least 4 hours of respiratory support with supplemental oxygen, continuous positive airway pressure, or ventilation at the first 24 hours of life

Secondary Outcomes

  • Number of Women That Show Polyhydramnios During Pregnancy Not Related to Known Fetal Anomaly(From enrollment to delivery)
  • Number of Women That Experience Pregnancy Induced Hypertension(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women That Experience Eclampsia: Seizures(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women Admitted Due to Poor Glucose Control(From enrollment up to delivery)
  • Number of Women With Primary Cesarean Section(at time of birth)
  • Number of Women With Postpartum Hemorrhage: Defined as Greater Then 1000ml(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women With Endometritis(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women With Wound Complications(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women With Diagnosis of Type 2 Diabetes During Postpartum(birth to 6 weeks postpartum)
  • Number of Women That Have Preterm Birth(at time of birth)
  • Number of Women That Undergo Induced Labor(at time of birth)
  • Feasibility as Assessed by the Number of Participants Who Complete the CGM Diagnostic Testing(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women That Use Diabetic Medication During Pregnancy(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Neonates With Apgar Score Less Than 7(5 minutes after birth)
  • Number of Neonates That Are Admitted to the Neonatal Intensive Care Unit (NICU)(birth to time of discharge from NICU (about 15 days))
  • NICU Length of Stay(birth to time of discharge from NICU (about 15 days))
  • Number of Neonates With Hyperbilirubinemia Requiring Phototherapy(birth to discharge (about 3-15 days))
  • Number of Neonates With Need for Intravenous or Oral Administration Glucose Therapy(birth to discharge (about 3-15 days))
  • Number of Neonates That Are Small for Gestational Age(at time of birth)
  • Number of Participants Who Breastfed Their Babies(from birth to 6 weeks postpartum)
  • Number of Participants Who Formula Fed Their Babies(from birth to 6 weeks postpartum)
  • Maximum Bilirubin Level - Neonates(birth to discharge (about 3 -15 days))
  • Cord Arterial pH(at time of birth)
  • Number of Neonates With Polycythemia(birth to discharge (about 3 -15 days))
  • Number of Women That Experience Preeclampsia With Severe Features(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women That Experience Super Imposed Preeclampsia(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Women With Need for Blood Transfusion(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Number of Participants With Ultrasound Diagnosis of Estimated Fetal Weight >90%Ile in the Third Trimester(Third trimester (≥28 weeks gestation through delivery))
  • Number of Women That Experience HELLP Syndrome(From enrollment to 6 weeks post partum, on average 21 weeks)
  • Cord Venous pH(at time of birth)
  • Total Health System Costs for Mothers and Infants(From enrollment to 6 weeks post partum, on average 21 weeks)

Study Sites (1)

Loading locations...

Similar Trials